Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Atypical MDR]

A Yokomizo1, K Taniguchi, S Hasegawa

  • 1Dept. of Biochemistry, School of Medicine, Kyusyu University, Fukuoka, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan.

ESMO real world data and digital oncology·2026
Same author

Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.

Prostate cancer and prostatic diseases·2016
Same author

Laparoscopic en bloc excision of gastrointestinal stromal tumors of the rectum after neoadjuvant imatinib therapy: anteriorly extended intersphincteric resection combined with partial resection of the prostate.

Techniques in coloproctology·2015
Same author

EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer.

Prostate cancer and prostatic diseases·2014
Same author

The close association of pi-class glutathione S-transferase with drug sensitivity to alkylating agents and cisplatin in human cancer cells.

International journal of oncology·2011

Multiple drug resistance (MDR) hinders cancer chemotherapy. Atypical MDR involves altered DNA topoisomerase II and the MRP gene, independent of P-glycoprotein.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multiple drug resistance (MDR) is a significant challenge in cancer treatment.
  • The MDR-1 gene encodes P-glycoprotein, a transporter protein often overexpressed in MDR cancer cells.
  • Atypical MDR (atMDR) occurs in cells lacking P-glycoprotein overexpression.

Purpose of the Study:

  • To investigate the mechanisms underlying atypical MDR.
  • To explore the role of DNA topoisomerase II and the MRP gene in atMDR development.

Main Methods:

  • Analysis of MDR cancer cell lines.
  • Assessment of P-glycoprotein expression.
  • Evaluation of DNA topoisomerase II activity.
  • Investigation of the ATP binding cassette (ABC) transporter superfamily, including the MRP gene.

Related Experiment Videos

Main Results:

  • atMDR can arise independently of P-glycoprotein.
  • Altered DNA topoisomerase II is implicated in some cases of atMDR.
  • The MRP gene, a member of the ABC transporter family, is newly identified as involved in atMDR in cells lacking P-glycoprotein and altered topoisomerase II.

Conclusions:

  • Atypical MDR involves complex mechanisms beyond P-glycoprotein.
  • The MRP gene represents a novel target for overcoming atMDR in specific cancer contexts.